



# HELP YOUR PATIENTS ENROLL IN THE ILARIS<sup>®</sup> (canakinumab) CO-PAY PROGRAM

**Eligible patients may pay a co-pay as little as \$30\***

Eligible patients pay as little as \$30 per month, subject to an annual cap. Patients who are insured through federal or state programs are not eligible.\*

**ILARIS<sup>®</sup>**  
(canakinumab)  
150 mg subcutaneous injection

\*Limitations apply. See Program Terms and Conditions on the ILARIS Start Form available at [www.ilarishcp.com/access](http://www.ilarishcp.com/access). This offer is not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice.


# ONE CARD, MULTIPLE PATHWAYS

Whether co-pay claims are managed by the office or the patient, there's a variety of ways to access co-pay support for ILARIS<sup>®</sup>.

## HCP-Managed Claims

If your office will manage co-pay claims, you can initiate enrollment through the **Co-Pay Portal** or the Start Form. Claims can then be managed through the portal or by fax.

### HCP-Managed Co-Pay Pathways




**Our Co-Pay Program provides the flexibility to manage co-pay claims in multiple ways that fit your workflow, whether through your office or managed by the patient.**

## Patient-Managed Claims

If your office is not managing co-pay claims on your patient's behalf, patients are able to pay up front and get reimbursed via the ILARIS<sup>®</sup> Co-Pay Program. Your patients can manage claim reimbursement in 2 ways:

- **Patient Co-Pay Claim Form**
- Patient rebate online at [Reimburse.patientsavings.com](https://Reimburse.patientsavings.com)

### Patient-Managed Co-Pay Pathway



If you are obtaining ILARIS through a specialty pharmacy (SP) (white bagging), the Co-Pay Card needs to be provided to the SP for them to manage claims.

- Your practice should provide the Co-Pay Card number when sending over the prescription
- The patient can also provide the number if contacted by the SP

**While these graphics represent the most common pathways, others do exist.  
See next page for other scenarios to keep in mind.**

# KEY CONSIDERATIONS FOR CO-PAY CLAIM SUBMISSIONS



## HCP Enrollment via the Co-Pay Portal

- The most streamlined pathway for ILARIS® is the Co-Pay Portal
- If your patient already has a Co-Pay Card number, use the number provided



## Patients Who Self-Enroll

- For patients who self-enroll through ILARIS Companion or a Start Form, claims can be managed by the patient or their HCP

If you have questions about ILARIS Companion services, contact a program representative, **Monday to Friday, 9:00 AM to 6:00 PM ET.**



**1-866-972-8315**

\*Limitations apply. Valid only for those with private insurance. The Program includes the Co-pay Card, Payment Card (if applicable), and Rebate, with a combined annual limit of \$36,000. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid: (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.



Novartis Pharmaceuticals Corporation  
East Hanover, New Jersey 07936-1080

© 2024 Novartis

8/24

FA-11236166

**ILARIS**  
(canakinumab)  
150 mg subcutaneous injection